secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0000950170-23-009469
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla reports FY2022 net loss $106.5M, cash $215.5M; advances CAB-ADC and bispecific trials
--------------------------------------------------------------------------------

- Net loss Q4 2022 $27.5M, full year $106.5M, vs Q4 2021 $23.4M and FY2021 $95.4M.
- R&D expenses FY2022 $79.3M, up from $58.3M in FY2021, driven by clinical development.
- Cash $215.5M at year-end 2022; expected to fund operations into 2025.
- Cleared DLT for BA3011 dose-intensive schedule; LMS readout 2H23; UPS registrational Phase 2 start in 1H23.
- FDA cleared IND for BA3182 (CAB-EpCAMxCD3 TCE); FPI Phase 1 in 1H23. BA3021 NSCLC and BA3071 Phase 2 data in 2H23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000095017023009469/0000950170-23-009469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000095017023009469/bcab-20230323.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer